Dianthus Therapeutics, Inc.

Dianthus Therapeutics is a biotechnology company dedicated to developing novel complement therapeutics with improved selectivity and potency. Their lead antibody, DNTH103, is a long-acting monoclonal antibody designed to potently and selectively inhibit the active form of C1s, a key protein in the classical complement pathway. DNTH103 is being investigated for the treatment of several neuromuscular disorders, including Generalized Myasthenia Gravis (gMG), Multifocal Motor Neuropathy (MMN), and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Dianthus is headquartered in New York City with offices in Waltham, MA, and offers flexible work arrangements including hybrid and fully remote opportunities. They are committed to building a diverse team and creating a work environment that fosters growth and innovation. The company is driven by a mission to improve the lives of patients suffering from rare and severe autoimmune diseases through their cutting-edge complement therapeutics.

Dianthus Therapeutics offers flexible work arrangements to its employees, including hybrid and fully remote options. This allows employees to balance their work and personal lives, providing them with the freedom to choose the work environment that best suits their needs. The company's headquarters are in New York City and Waltham, MA, but the flexibility in work arrangements makes it possible for employees to work from other locations as well.

Dianthus Therapeutics offers a comprehensive benefits package that includes health insurance, dental and vision coverage, all covered at 100%. Employees also have access to Health Savings Accounts with company contributions available, as well as various FSA options. Dianthus provides a 401K plan, life insurance, long and short-term disability insurance, and generous family leave. Their work-life blend is also emphasized, with flexible working environments, hybrid and remote work options, and a generous time off policy that includes four weeks of PTO, plus a weeklong summer and holiday shutdown.

Dianthus Therapeutics is a biotechnology company focused on developing novel and highly differentiated monoclonal antibodies that target complement proteins, aiming to create next-generation complement therapies for the treatment of rare and severe autoimmune diseases. They are committed to harnessing the power of selectivity in complement therapeutics, engineering antibodies with extended half-life, improved potency, and high specificity to drive disease pathology, ultimately improving the lives of patients.

Dianthus Therapeutics cultivates a culture that values innovation, collaboration, and a deep commitment to improving the lives of patients. Their core values emphasize trust, respect, and perseverance, creating an environment where team members feel empowered to take on challenges creatively and with enthusiasm. Dianthus fosters a work-life blend with flexible working arrangements and robust benefits, demonstrating their dedication to employee well-being and professional growth.

Dianthus Therapeutics is committed to fostering a diverse, equitable, and inclusive workplace that values the unique perspectives of each individual. They believe that cultivating meaningful dialogue and respect for diverse backgrounds are essential for unlocking the full potential of complement therapies. Their commitment extends to building a diverse team and creating a work environment that promotes personal and professional growth for all. They believe that they are better together and strive to create a workplace where everyone can thrive.